Mark L. Jacobson

COO Mark L. Jacobson sells 4,750 shares for $1.1M at AXSM via scheduled 10b5-1 plan; retains 230,141 option shares

Mark L. Jacobson, Chief Operating Officer, executed 2 separate sales totaling 4,750 shares for $1,082,770.92 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings to zero while retaining 230,141 shares through stock option positions. The sales occurred at a blended average price of $227.95, below the current price of $255.17 and well below the 52-week high of $257.92. Jacobson's prior trades at AXSM show mixed 30-day outcomes (ranging from -3.4% to +11.9%) but consistently positive 90-day returns (ranging from +13.3% to +44.9%), suggesting the stock has tended to appreciate meaningfully in the months following his historical sales at this ticker. The company remains unprofitable despite strong revenue growth of +65.6% year-over-year and a substantial market cap of $13.1B, reflecting a high-growth but pre-profitability profile typical of biotech/therapeutics firms.

COO Jacobson Mark L. sells entire 35,378-share holding of AXSM for $5.7M under 10b5-1 plan on 2026-02-26

Chief Operating Officer Jacobson Mark L. liquidated his complete equity stake in Axsome Therapeutics, selling 35,378 shares at $161.88 for total proceeds of $5,726,990.64 on 2026-02-26. The transaction was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. This represents a 100.0% reduction in his shareholding, reducing post-transaction holdings to 0 shares from 35,378 shares pre-transaction. While complete insider stake liquidations warrant investor attention, the scheduled nature of the 10b5-1 plan indicates this sale follows a predetermined execution structure unrelated to current market or company conditions.

AXSM COO Mark L. Jacobson sold 10,000 shares at $115.96; holds zero post-transaction; all prior AXSM sales underperformed (90d avg +13.8%, 0 of 3 well-timed).

Jacobson's sale of 10,000 shares ($1.2M) eliminates his entire position in AXSM and represents a complete exit. His prior three measurable AXSM sales (May 27, May 28, June 9, 2025) all saw the stock rise substantially over 90 days (+11.1%, +17.1%, +13.3%), meaning zero of those sales were well-timed. This transaction's timing relative to subsequent price action will establish whether the pattern continues. The company remains unprofitable ($-48.0M net income last quarter; annual revenue growth +42.5%), trading at $117.49 today (−14.7% from 52-week high), which adds context but does not confirm any forward directional signal from the trade itself.

COO Mark Jacobson sold 45,783 shares for $5.2M via 10b5-1 plan, liquidating full position

Mark Jacobson, Chief Operating Officer, executed two separate sales totaling 45,783 shares for $5,241,126.77 on 2025-09-16 at an average price of $114.48. This transaction eliminates his entire shareholding post-execution (0 shares remaining vs 45,783 pre-transaction). The filing is flagged as part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled in advance rather than discretionary decisions. Complete position liquidation by a senior executive merits attention from investors monitoring insider ownership changes, though the scheduled nature of the plan removes timing-based inference.

COO Mark L. Jacobson sold 25,000 shares of AXSM at $110.44 under 10b5-1 plan; holdings drop to 5,783 shares (-81.2%)

Chief Operating Officer Mark L. Jacobson sold 25,000 shares (25.0K shares) for a total value of $2,761,000.00 ($2.8M), reducing his post-transaction holdings to 5,783 shares (5.8K shares) from 30,783 shares (30.8K shares). This transaction is executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled in advance rather than a discretionary trade decision made in real-time. The substantial reduction of 81.2% versus pre-transaction holdings represents a meaningful decrease in the executive's direct equity stake, although the scheduled nature limits inferences about timing or conviction.

COO Mark L. Jacobson sells 40,673 shares for $4,232,636.18 via 10b5-1 plan at AXSM

Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, executed two separate sales totaling 40,673 shares for $4,232,636.18 on 2025-05-27 and 2025-05-28, reducing his holdings from 46,456 shares to 5,783 shares—a decline of 87.6%. This transaction is governed by a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled in advance rather than discretionary decisions made in response to current market conditions. The magnitude of the reduction—disposing of the vast majority of his shareholding—represents a material shift in insider exposure to the company, though the scheduled nature of the plan means the timing reflects pre-established parameters rather than near-term judgment.

COO Mark Jacobson sold 47,739 shares of AXSM for $4.0M under pre-arranged 10b5-1 plan

Jacobson Mark L., Chief Operating Officer, executed a scheduled sale of 47,739 shares at $84.26 on 2024-08-09 under a pre-arranged 10b5-1 trading plan, reducing his holdings from 53,522 shares to 5,783 shares (a -89.2% reduction in his pre-transaction position). Because this transaction is part of a pre-arranged trading plan rather than a discretionary choice, it does not reflect timing-based judgment by the insider. The substantial reduction in the COO's stake—from 53.5K shares to 5.8K shares—represents a material shift in his financial exposure to the company, though the scheduled nature of the plan means the sale timing was determined in advance rather than based on current conditions.